Tenax Therapeutics (NASDAQ:TENX) Insider Stuart Rich Acquires 2,500 Shares of Stock

Tenax Therapeutics, Inc. (NASDAQ:TENX) insider Stuart Rich acquired 2,500 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The shares were acquired at an average cost of $9.20 per share, with a total value of $23,000.00. Following the completion of the transaction, the insider directly owned 2,500 shares in the company, valued at approximately $23,000. The trade was a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Stuart Rich also recently made the following trade(s):

• On Wednesday, December 3rd, Stuart Rich bought 1,500 shares of Tenax Therapeutics stock. The stock was bought at an average cost of $9.08 per share, for a total transaction of $13,620.00.
• On Tuesday, December 2nd, Stuart Rich bought 1,000 shares of Tenax Therapeutics stock. The shares were bought at an average cost of $9.01 per share, with a total value of $9,010.00.

Tenax Therapeutics Stock Performance

Tenax Therapeutics stock opened at $9.65 on Friday. The company’s 50 day simple moving average is $7.71 and its 200-day simple moving average is $6.61. Tenax Therapeutics, Inc. has a 1 year low of $4.63 and a 1 year high of $9.91. The company has a market capitalization of $60.22 million, a price-to-earnings ratio of -8.54 and a beta of 1.55.

Tenax Therapeutics (NASDAQ:TENX) last posted its quarterly earnings data on Wednesday, November 12th. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.33) by $0.93. Equities analysts expect that Tenax Therapeutics, Inc. will post -0.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on TENX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tenax Therapeutics in a research note on Monday. Guggenheim lowered their target price on Tenax Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Thursday, August 14th. Piper Sandler started coverage on Tenax Therapeutics in a research note on Monday, September 8th. They set an “overweight” rating and a $20.00 price target for the company. Finally, Wall Street Zen raised Tenax Therapeutics to a “sell” rating in a report on Saturday, October 25th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Institutional Trading of Tenax Therapeutics

A number of institutional investors have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in Tenax Therapeutics during the third quarter worth $92,000. Citadel Advisors LLC lifted its holdings in Tenax Therapeutics by 318.1% in the third quarter. Citadel Advisors LLC now owns 43,253 shares of the specialty pharmaceutical company’s stock valued at $329,000 after acquiring an additional 32,908 shares during the period. ADAR1 Capital Management LLC boosted its position in shares of Tenax Therapeutics by 98.1% during the 1st quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock worth $450,000 after purchasing an additional 34,048 shares in the last quarter. Woodline Partners LP acquired a new position in shares of Tenax Therapeutics during the 3rd quarter worth $671,000. Finally, Millennium Management LLC grew its stake in shares of Tenax Therapeutics by 34.2% during the 3rd quarter. Millennium Management LLC now owns 313,712 shares of the specialty pharmaceutical company’s stock worth $2,387,000 after purchasing an additional 79,998 shares during the period. 1.67% of the stock is currently owned by hedge funds and other institutional investors.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.